Molecular Dx

While most NGS providers limit their annotated reports to one mutation-one drug associations that address targeted therapeutics, Cellworks’ biosimulation platform permits an assessment of all cancer therapies, including radiation, chemotherapy, and immunotherapy.

Research shows that abnormal gene expression changes can occur before islet autoimmunity or type 1 diabetes is present in susceptible children, which could help predict who is most likely to progress to full-blown diabetes.

To explore the potential role of SORBS2 in congenital heart disease, researchers suppressed the gene in developing human heart cells grown in the laboratory. This led to the development of abnormally shaped heart cells and interfered with the ability of cardiac muscle cells to undergo necessary changes in gene expression.

Along with identifying these putative cell of origin for a variety of RCCs, the analysis also revealed pathways and interactions within the tumor microenvironment that predicted whether the tumor would respond to immunotherapy.

A technique combining digital PCR and CRISPR based detection with a LAMP-style simple amplification detects SARS-CoV-2 and other viruses quickly and specifically without the time consuming and costly need for thermal cycling of RT-PCR.

A single biomarker—neurofilament light chain—can indicate the presence of underlying neurodegeneration with excellent accuracy across several different disorders, according to new research.

Amgen's Lumakras, a small molecule just approved for clinical use by the FDA, becomes the first targeted therapy for lung cancer patients with KRAS mutations, an urgently needed option for patients with limited therapeutic options.

U.S. researchers have developed an antiviral candidate drug targeting iron-sulfur clusters needed for SARS-CoV-2 RNA replicase to function properly and for the virus to reproduce successfully.

Helix has developed an end-to-end genomics platform designed to advance genomic research and accelerate the integration of genomic data into clinical care through its unique Sequence Once, Query Often model.

The findings are part of the U.K. Deciphering Developmental Disorders (DDD) study, which recruited children with undiagnosed developmental disorders between 2010-2015 to see if new genetic technologies can help doctors understand why patients get developmental disorders.